Are your clinical trials risky? Are costs running away?
It’s very tricky to estimate clinical trial costs before a trial is run.
Try our free cost calculator. This is a regression model, trained on real clinical trial data.
| Trial is for condition | |
| Phase | |
| Vaccine trial? | |
| Country | |
| Sample size | |
| Number of interventions |
The clinical trial risk tool will let you upload a PDF protocol and will directly identify some risk and cost features.
Unlike other clinical trial cost calculators you may find online, our clinical trial cost models are regression models trained on past trials. You can download the training dataset here - the original source is here.
Here’s a preview of our training data that we used to develop our regression models:
| Indication | Technology | NCT# | Tech II | Enrollment | Trial Phase | Total Cost | Per Patient Cost ($PP) | Source for this Data | Name of the Source | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Advanced Myeloid Malignancy | biologic drug | - | 30 | Phase 1 | $328,000.00 | $10,933 | doc | SEC agreements | |||
| Blood Cancer | biologic drug | NCT03483324 | 9 | Phase 1 | $5,000,000.00 | $555,556 | doc | CIRM | |||
| Blood Cancer | biologic drug | NCT03925935 | 24 | Phase 1 | $6,192,579.00 | $258,024 | doc | CIRM | |||
| B cell cancers, Leukemia | biologic drug | NCT03088878 | 156 | Phase 1/2 | $18,292,674.00 | $117,261 | doc | CIRM | |||
| Blood Cancer | biologic drug | NCT02222688 | 26 | Phase 1 | $4,179,598.00 | $160,754 | doc | CIRM | |||
| Colon Cancer | biologic drug | NCT02953782 | 112 | Phase 1/2 | $10,234,048.00 | $91,375 | doc | CIRM | |||
| Leukemia, Acute Myeloid (AML) | biologic drug | NCT03248479 | 96 | Phase 1 | $5,000,000.00 | $52,083 | doc | CIRM | |||
| Blood Cancer, Solid Tumors | biologic drug | NCT02216409 | 88 | Phase 1 | $6,505,568.00 | $73,927 | doc | CIRM | |||
| Breast Cancer | biologic drug | NCT00781612 | 720 | Phase 3 | - | $104,186.49 | https://doc | KEI FOIA Response/University of Colorad | |||
| Stage IV Melanoma | cell therapy | NCT00438984 | 11 | Phase 1 | $936,164.00 | $85,106 | doc | FOIA’d NIH grants | |||
The Clinical Trial Risk Tool:
We originally developed the Clinical Trial Risk Tool to estimate costs of Tuberculosis and HIV trials. In 2024, we extended the scope of the tool to cover other disease indications including COVID, Cystic fibrosis, Enteric and diarrheal diseases clinical trials cost models, Influenza clinical trials cost modelling, Malaria clinical trials cost models, Motor neurone disease, Multiple sclerosis, Neglected tropical diseases clinical trials cost modelling, Oncology, and Polio clinical trials cost modelling.
In addition to cost estimation, we’re looking at RCT risk assessment, informativeness and RCT complexity.
When you’re planning a clinical trial, you have to write the protocol.
This is a PDF document which is 200 pages long.
It says what drug you are testing, who will participate in your trial, over what time period, and what they will be required to do. It may also say how you will manufacture the drug, how it will be delivered, where the trial will take place, and how you will analyse the data.
If you want an organisation to fund your trial (a sponsor), they will need to read the protocol and estimate the cost, and be satisfied that the trial is not too risky.
To complete this risk assessment and cost assessment, you will need experts in multiple fields to read and assess the protocol. This is subjective (different people might come to different conclusions) and it’s slow.
The Clinical Trial Risk Tool unifies the technical knowledge in the protocol (medical or statistical information) with the business knowledge (finances, risk management).
Imagine you could have a tool which could read your protocols and estimate the cost and risk, immediately!
If you work for the trial sponsor, this helps you triage the protocols that you receive from investigators, identifying who’s worth pursuing
In a pharmaceutical company, this helps your business plan cash flow and quantify and diversify risk.
If you are investing in pharmaceutical development, this helps you understand your exposure to risk
If you’re a CRO (contract research organisation, i.e. the company that is contracted to run the trials), you can prepare quotes and cost estimates for your clients (pharma companies) quickly and easily.
This post originally appeared on Fast Data Science’s blog on LinkedIn. Clinical trials are vital for advancing medical innovation, yet they often face significant hurdles, including ensuring patient safety, adhering to regulatory requirements, controlling costs, and maintaining efficiency. Traditional risk assessment methods frequently need to be revised to address these complexities. Artificial Intelligence (AI) is transforming clinical trial management, offering data-driven solutions to predict and mitigate risks. AI-powered tools like the Clinical Trial Risk Tool have revolutionised trial planning and execution.
This post originally appeared on Fast Data Science’s blog on LinkedIn. Clinical trial protocols are often long, detailed documents—sometimes 200 pages—filled with vital information about sample size, treatment methods, and statistical plans. These protocols ensure the effective conduct of trials, but their complexity increases the time needed for manual reviews and the risk of human error. This is where Natural Language Processing (NLP) steps in. NLP enables machines to “read” unstructured data, such as clinical trial protocols, and extract key insights.
This post originally appeared on Fast Data Science’s blog on LinkedIn. Clinical trials, the backbone of medical science advancement, often grapple with high costs, complexity, and lengthy timelines. Fast Data Science presents Fast Clinical AI, a game-changing solution that harnesses the power of Natural Language Processing (NLP) and predictive modelling to tackle these challenges head-on. Streamlined Data Extraction and Analysis: Fast Clinical AI automates the extraction of critical information from trial protocols, significantly reducing manual efforts.
